Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Galectin-3 as a Biomarker in Patients With Chagas Disease

This study has been completed.
Information provided by (Responsible Party):
Milena Botelho Pereira Soares, Hospital Sao Rafael Identifier:
First received: April 18, 2013
Last updated: October 9, 2015
Last verified: October 2015
The purpose of this study is to analyze the efficacy of Galectin-3 as a biomarker on the Chagas Disease prognosis. This analysis will be done through the correlation between the plasmatic levels of this molecule with functional and laboratory tests.

Chagas Disease.

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Validation of Galectin-3 as a Biomarker for Determining Patients Prognosis With Chagas Disease

Resource links provided by NLM:

Further study details as provided by Hospital Sao Rafael:

Primary Outcome Measures:
  • Correlation of plasmatic levels of Galectin-3 with the percentage of heart fibrosis [ Time Frame: One year ]
    Mensuration of heart fibrosis percentage with Magnetic Resonance Imaging

Secondary Outcome Measures:
  • Correlation of plasmatic levels of Galectin-3 with the functional capacity of the heart [ Time Frame: One year ]
    Mensuration of the functional capacity with treadmill test

  • Correlation of plasmatic levels of Galectin-3 with the serum levels of Pro-BNP. [ Time Frame: One year ]
  • Correlation of plasmatic levels of Galectin-3 with the serum levels of TNF-alpha [ Time Frame: One year ]
  • Correlation of plasmatic levels of Galectin-3 with the serum levels of IFN-gamma. [ Time Frame: One year ]

Biospecimen Retention:   Samples With DNA
Plasma, Serum, Whole Blood

Enrollment: 60
Study Start Date: January 2011
Study Completion Date: June 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Patients with Chagas disease diagnosis
Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.

Detailed Description:

Previous studies indicate that activated macrophages secrete Galectin-3, a molecule that is involved in the development of fibrosis and tissue rearrangement in the liver, kidney and the heart. Its plasmatic levels are increased on patients with acute decompensated heart failure. These observations suggest that measuring levels of Galectin-3 in patients with cardiac diseases can be useful to determine their prognosis. To investigate the role of this new biomarker in Chagas Disease, we will study a Chagas Disease population (including patients with the indeterminate and cardiac form of the disease). The assessment of the prognostic value of Galectin-3 will be done through the comparison between its plasmatic levels and each patients's clinical evaluation, disease severity, inflammatory biomarkers and cardiac function tests.

The patients included in the study must at first sign the written consent. They shall be accompanied in the specialized outpatient clinics for Chagas disease - Hospital São Rafael - Centro de Biotecnologia e Terapia Celular. They will be submitted to several tests, including:

  • Collection of Blood samples for biochemical analysis;
  • Electrocardiogram;
  • Holter Electrocardiogram;
  • Echocardiogram;
  • Treadmill Test;
  • X-Ray Imaging;
  • Magnetic Resonance Imaging;
  • Evaluation of the quality of life through the application of questionnaires (SF 36 and the Minnesota Living With Heart Failure Questionnaire).

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Tertiary Hospital

Inclusion Criteria:

  • Chagas Disease diagnosis confirmed by 2 different serologies
  • Diagnosis of indeterminate form or cardiac form, with and without ventricular dysfunction.

Exclusion Criteria:

  • Significant valve disease defined as aortic stenosis with a gradient of VE/Ao > 50 mmHg
  • Mitral stenosis with a valve area inferior than 1,5 cm2
  • Severe or moderate aortic and/or mitral regurgitation
  • Chronic use of immunosuppressive agents
  • Dialysis treatment of terminal renal failure
  • Fever on the last 48 hours or evidence of systemic infection in activity according to the definition of sepsis of the ACCP/SCCM (American College os Chest Physicians/Society of Critical Care Medicine)
  • Current abusive use of alcohol or illicit drugs (Based on the DSM IV)
  • Any other comorbidities that impact patient's survival within the next 2 years
  • Liver disease in activity
  • Continuous use of steroids as treatment for COPD
  • Hematologic, neoplastic or bone diseases
  • Homeostasis disturbances
  • Inflammatory diseases or chronic infectious diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01842854

Hospital São Rafael
Salvador, Bahia, Brazil, 41253-190
Sponsors and Collaborators
Hospital Sao Rafael
Principal Investigator: Milena Botelho Pereira Soares, PhD Hospital São Rafael
Study Director: Ricardo Ribeiro dos Santos, MD, PhD Hospital São Rafael
Study Chair: Ticiana Ferreira Larocca, MD, MSC Hospital São Rafael
Study Chair: Márcia Maria Noya Rabelo, MD, MSC Hospital São Rafael
Study Chair: Luís Cláudio Lemos Correia, MD, PhD Hospital São Rafael
Study Chair: Bruno Solano de Freitas Souza, MD, MSC Hospital São Rafael
Study Chair: Carolina Thé Macedo, MD Hospital São Rafael
  More Information

Responsible Party: Milena Botelho Pereira Soares, PhD, Hospital Sao Rafael Identifier: NCT01842854     History of Changes
Other Study ID Numbers: CEP-41-10
Galectin-Chagas ( Registry Identifier: CEP HSR 41-10 )
Study First Received: April 18, 2013
Last Updated: October 9, 2015

Keywords provided by Hospital Sao Rafael:
Chagas disease

Additional relevant MeSH terms:
Chagas Disease
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases processed this record on April 28, 2017